Characteristics and outcomes of hospitalised patients with acute kidney injury and COVID-19.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 06 08 2020
accepted: 16 10 2020
entrez: 3 11 2020
pubmed: 4 11 2020
medline: 18 11 2020
Statut: epublish

Résumé

COVID-19 has spread globally to now be considered a pandemic by the World Health Organisation. Initially patients appeared to have a respiratory limited disease but there are now increasing reports of multiple organ involvement including renal disease in association with COVID-19. We studied the development and outcomes of acute kidney injury (AKI) in patients with COVID-19, in a large multicultural city hospital trust in the UK, to better understand the role renal disease has in the disease process. This was a retrospective review using electronic records and laboratory data of adult patients admitted to the four Manchester University Foundation Trust Hospitals between March 10 and April 30 2020 with a diagnosis of COVID-19. Records were reviewed for baseline characteristics, medications, comorbidities, social deprivation index, observations, biochemistry and outcomes including mortality, admission to critical care, mechanical ventilation and the need for renal replacement therapy. There were 1032 patients included in the study of whom 210 (20.3%) had AKI in association with the diagnosis of COVID-19. The overall mortality with AKI was considerably higher at 52.4% compared to 26.3% without AKI (p-value <0.001). More patients with AKI required escalation to critical care (34.8% vs 11.2%, p-value <0.001). Following admission to critical care those with AKI were more likely to die (54.8% vs 25.0%, p-value <0.001) and more likely to require mechanical ventilation (86.3% vs 66.3%, p-value 0.006). We have shown that the development of AKI is associated with dramatically worse outcomes for patients, in both mortality and the requirement for critical care. Patients with COVID-19 presenting with, or at risk of AKI should be closely monitored and appropriately managed to prevent any decline in renal function, given the significant risk of deterioration and death.

Identifiants

pubmed: 33141867
doi: 10.1371/journal.pone.0241544
pii: PONE-D-20-24600
pmc: PMC7608889
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0241544

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Am Soc Nephrol. 2020 Sep;31(9):1948-1958
pubmed: 32660970
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet Psychiatry. 2020 Oct;7(10):875-882
pubmed: 32593341
Nephrol Dial Transplant. 2012 Dec;27(12):4263-72
pubmed: 23045432
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
Kidney Int Rep. 2020 Apr 09;5(6):935-939
pubmed: 32292867
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
Int J Clin Pract. 2016 Apr;70(4):330-9
pubmed: 26799821
BMJ. 2020 Jun 4;369:m2119
pubmed: 32499317
medRxiv. 2020 May 08;:
pubmed: 32511564
Am J Nephrol. 2020;51(5):343-348
pubmed: 32229732
Clin Kidney J. 2020 Jun 06;13(3):354-361
pubmed: 32695326
Invest Radiol. 2020 Jun;55(6):327-331
pubmed: 32118615
J Am Soc Nephrol. 2020 Jun;31(6):1157-1165
pubmed: 32345702
J Am Soc Nephrol. 2020 Jul;31(7):1380-1383
pubmed: 32366514
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Lancet Respir Med. 2020 Jul;8(7):738-742
pubmed: 32416769
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Blood Purif. 2021;50(1):102-109
pubmed: 32659757
BMJ Qual Improv Rep. 2017 May 25;6(1):
pubmed: 28607684
Nat Rev Nephrol. 2020 Jun;16(6):308-310
pubmed: 32273593
Lancet Respir Med. 2020 Jun;8(6):e46-e47
pubmed: 32353251
AJR Am J Roentgenol. 2020 May;214(5):1072-1077
pubmed: 32125873
Intensive Care Med. 2017 Jun;43(6):855-866
pubmed: 28466146
J Crit Care. 2020 Dec;60:103-105
pubmed: 32795841
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
BMC Nephrol. 2014 May 29;15:84
pubmed: 24885247
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379
pubmed: 32242738
J Med Virol. 2020 Jul;92(7):797-806
pubmed: 32198776

Auteurs

Patrick Hamilton (P)

Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Manchester Academic Health Sciences Centre (MAHSC), Manchester, United Kingdom.
Division of Cell Matrix Biology and Regenerative Medicine, Wellcome Centre for Cell-Matrix Research, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, United Kingdom.

Prasanna Hanumapura (P)

Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Manchester Academic Health Sciences Centre (MAHSC), Manchester, United Kingdom.

Laveena Castelino (L)

Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

Robert Henney (R)

Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Manchester Academic Health Sciences Centre (MAHSC), Manchester, United Kingdom.

Kathrine Parker (K)

Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Manchester Academic Health Sciences Centre (MAHSC), Manchester, United Kingdom.

Mukesh Kumar (M)

Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

Michelle Murphy (M)

Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

Tamer Al-Sayed (T)

Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

Sarah Pinnington (S)

Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

Tim Felton (T)

Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Intensive Care Unit, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom.

Rachael Challiner (R)

Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Manchester Academic Health Sciences Centre (MAHSC), Manchester, United Kingdom.

Leonard Ebah (L)

Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Manchester Academic Health Sciences Centre (MAHSC), Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH